Pediatric Praziquantel Consortium

Pediatric Praziquantel Consortium to participate in ISNTD Connect GSA webinar

04 November 2020

The Pediatric Praziquantel Consortium has been invited to participate in a webinar jointly hosted by the...

Pediatric Praziquantel Consortium to participate in WHO webinar on Innovation

15 September 2020

The Pediatric Praziquantel Consortium is delighted to be participating in the upcoming WHO webinar on 18 September....

A new formulation to fight Schistosomiasis


A pediatric formulation of Praziquantel has been developed for schistosomiasis.
Video credits: The GHIT Fund

Vision

Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more

Mission

Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

The consortium established a pediatric drug development program, divided into three major steps: preclinical development, clinical development and registration and access.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.

Read more